Ariana Pelosci

Articles

Camrelizumab/Nab-POF Combo Increases R0 Resection Rates in Gastric/GEJ Cancer

January 25th 2025

Camrelizumab plus Nab-POF was associated with high rates of conversion to R0 resection and high 3-year survival rates in gastric and GEJ adenocarcinoma.

Single-Cycle Neoadjuvant Pembrolizumab Is Efficacious, Safe in dMMR Colon Cancer

January 25th 2025

Treatment with a single cycle of neoadjuvant pembrolizumab demonstrated a pCR rate of 44% in patients with dMMR colon cancer.

Neoadjuvant SCRT Plus Cadonilimab/Chemo Meets pCR End Point in pMMR/MSS Rectal Cancer

January 25th 2025

The phase 2 NeoCaCRT trial evaluating neoadjuvant SCRT plus cadonilimab/chemotherapy met its primary end point of pCR rate in locally advanced rectal cancer.

Addition of CRT to Chemotherapy Does Not Improve RFS in Resected Gallbladder Cancer

January 25th 2025

Relapse-free survival rates were not improved when chemoradiation was added to chemotherapy in resected gallbladder cancer, according to data from the ACCELERATE trial.

Pamrevlumab Plus Chemo Fails to Improve Survival in Unresectable Locally Advanced Pancreatic Cancer

January 24th 2025

Pamrevlumab plus chemotherapy failed to demonstrate a survival benefit in patients with locally advanced, unresectable pancreatic cancer.

Surufatinib Plus TAS-102 Displays Activity, Safety in Later-Line Metastatic PDAC

January 24th 2025

Surufatinib with TAS-102 produced promising survival outcomes and manageable toxicity as later-line therapy for a small cohort of patients with PDAC.

Addition of Camrelizumab and Rivoceranib to TACE Boosts PFS in Unresectable HCC

January 24th 2025

TACE with camrelizumab and rivoceranib elicited a clinically meaningful PFS improvement among patients with unresectable HCC.

HR-1701 Plus Chemo Reduces Myelosuppression in HER2-Negative Gastric and GEJ Adenocarcinoma

January 23rd 2025

SHR-1701 plus CAPOX chemotherapy elicited fewer chemo delays and dose reductions and improved AE data vs placebo plus CAPOX in HER2-negative gastric/GEJ cancer.

Everolimus Plus Lanreotide Extends PFS in Advanced GEP-NETs

January 21st 2025

Everolimus plus lanreotide demonstrated an improved PFS compared with everolimus monotherapy in gastroenteropancreatic neuroendocrine tumors.

A Sense of Culture and Community Sparked a Passion in Genitourinary Oncology

December 27th 2024

A humble mindset of the contributions he has made to genitourinary cancer care, Christopher J. Logothetis, MD, is also working to shape the next generation’s minds of medicine to improve outcomes further.

Postoperative Radiation Therapy Improves HRQOL, Safety in Early-Stage HR+/HER2– Breast Cancer

December 16th 2024

Radiation therapy produced superior HRQOL outcomes and fewer toxicities vs endocrine therapy in older patients with stage I luminal-like breast cancer.

Neoadjuvant Niraparib Plus Dostarlimab Generates pCRs in BRCA+ ER+/HER2– Breast Cancer

December 13th 2024

Treatment with preoperative niraparib plus dostarlimab generated responses among patients with BRCA-mutant, ER-positive, HER2-negative breast cancer

Tamoxifen Reduces Ipsilateral Breast Recurrence in Good-Risk Ductal CIS

December 12th 2024

Tamoxifen reduced the risk of invasive ipsilateral breast recurrence in patients with good-risk ductal carcinoma in situ.

Risk-Reducing Surgery Improves Survival Outcomes in Younger BRCA+ Breast Cancer

December 11th 2024

Risk-reducing surgery improved survival outcomes in younger patients with breast cancer and a germline BRCA mutation.

First-Line Pirtobrutinib Plus Venetoclax/Obinutuzumab Generates High uMRD Rates in CLL

December 10th 2024

First-line pirtobrutinib plus venetoclax and obinutuzumab generated high uMRD6 remission rates among patients with chronic lymphocytic leukemia.

Piecing Together the Proper BTK Usage in CLL

November 13th 2024

Nicole Lamanna, MD, highlights various clinical trials underway evaluating new treatment options for patients with chronic lymphocytic leukemia.

IMA203 Produces Responses in Heavily Pretreated Advanced Melanoma, Other Solid Tumors

November 11th 2024

The investigational PRAME-targeted T-cell therapy IMA203 generated responses in melanoma and other solid tumors,

Temozolomide/Pembrolizumab Plus TTFields Leads to Tumor Control in Newly Diagnosed Glioblastoma

November 11th 2024

Patients with newly diagnosed glioblastoma had improved survival when treated with TTFields plus temozolomide and pembrolizumab.

E-602 Plus Cemiplimab Elicits Preliminary Antitumor Activity, Is Safe in PD-(L)1–Resistant Solid Tumors

November 11th 2024

E-602 plus cemiplimab elicited preliminary antitumor activity and had a tolerable safety profile in PD-(L)1–resistant solid tumors.

Frontline Dostarlimab/Chemo Maintains Numerical OS Benefit in Advanced NSCLC

November 8th 2024

Overall survival findings from the PERLA trial showed continued success with dostarlimab plus chemotherapy in patients with advanced non–small cell lung cancer.